Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

CORALreef Lipids: Enlicitide Reduces LDL-C in Patients With ASCVD, With Ann Marie Navar, MD, PhD

Enlicitide decanoate has demonstrated its efficacy in reducing 

low-density lipoprotein cholesterol (LDL-C)

 levels compared to placebo in patients with a history of or at risk for a major 

atherosclerotic cardiovascular disease (ASCVD)

 event, according to data from the phase 3 CORALreef Lipids trial.

Enlicitide is an oral macrocyclic peptide, designed to inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) and prevent it from binding to LDL-C receptors. In prior phase 1 and 2 trials, enlicitide demonstrated its efficacy in lowering LDL-C levels over the short term; the CORALreef Lipids trial examined the drug’s efficacy dover a 52-week period.

“My hope is that another agent that is really impressive in terms of LDL cholesterol lowering will help to actually get more clinicians to start thinking about prescribing non-statin drugs,” Ann Marie Navar, MD, PhD, associate professor, department of internal medicine, UT Southwestern Medical Center, told 

 in an exclusive interview. “Ideally, because enlicitide as a pill is easier to take, it may get over some of the provider inertia against prescribing non-statin therapy and help more people start getting to goal.”

CORALreef Lipids was a multinational, double-blind, randomized, placebo-controlled trial conducted across 168 sites in 14 countries worldwide. Patients were eligible for inclusion if they were aged ≥18 years and had a history of a major ASCVD event and an LDL-C level ≥55 mg/dL, or if they were at risk for a first ASCVD event and had an LDL-C ≥70 mg/dL. Exclusion criteria were active or recent treatment with a PCSK9 inhibitor, uncontrolled 

, active liver disease, or a triglyceride level ≥400 mg/dL at screening.

LDL-C levels were determined via a fasting lipid panel conducted at screening. Major ASCVD events were defined as acute coronary syndrome, coronary revascularization, myocardial infarction, and ischemic stroke, among others. The study’s primary endpoint was the mean percentage change in LDL-C from baseline to week 24. Key secondary endpoints included the mean change in LDL-C by week 52 and the mean percent change in levels of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B.

A total of 2912 patients were enrolled and randomly assigned in a 2:1 ratio to receive either enlicitide 20 mg or matching placebo for 52 weeks. Investigators instructed participants to take enlicitide or placebo in the morning on an empty stomach and to withhold food and beverages other than water for 30 minutes. The team conducted follow-up visits at baseline and at weeks 4, 8, 16, 24, 36, and 52.

Ultimately, 1831 participants in the enlicitide arm and 918 in the placebo arm completed the trial. Adherence to the full regimen was high and consistent across both arms, with an overall mean adherence of 97.2%. The mean LDL-C level was 95 +/- 38.8 mg/dL in the enlicitide group and 98.3 +/- 39.2 mg/dL in the placebo group. By week 24, the enlicitide group had reached a mean LDL-C level of 38.7 +/- 35.6 mg/dL, while the placebo group rose to 98.6 +/- 42.5 mg/dL. The mean percent change in the enlicitide group was -57.1% (95% CI, -61.8 to -52.5%) and 3% (95% CI, 0.9 to 5.1%) in the placebo group.

Due to the substantial treatment adherence documented in the study, investigators hope that the comparative simplicity of oral enlicitide will overcome the notorious prescription inertia present in dyslipidemia management.

“The main advantage comes in having multiple options for people, who can now choose what works for them,” Navar said. “Some people may prefer an injection, and they may be more adherent to an injection than a pill. Some people would prefer a pill over an injection. I think enabling patient choice will help with adherence, because if people are on the drug that they want to be on and the form they want to be on it in, I think they’re more likely to take it.”

Editor’s Note: Navar reports disclosures with Esperion Therapeutics, Bristol Myers Squibb, Amgen, Janssen Pharmaceuticals, Eli Lilly, Novo Nordisk, and others.

Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. New England Journal of Medicine. 2026;394(6):529-539. 

Ballantyne CM, Banka P, Mendez G, et al. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553-1564. 

Videos

Navar discusses the positive data from the phase 3 trial and emphasizes substantial treatment adherence throughout the 52-week period.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Dawn Eichenfield, MD, PhD, is a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at UC San Diego School of Medicine.

Paul Nghiem, MD, PhD, leads research at the UW Medicine South Lake Union (SLU) campus, and provides patient care at the Fred Hutch Cancer Center.

Walter J. Liszewski, MD, is an associate professor of dermatology and cancer epidemiology at Northwestern University Feinberg School of Medicine.

What’s Next in Dermatology? Dermatologists Weigh In On 2026

 are looking ahead to a year defined by expanding oral therapeutics, immunologic insights, next-generation biologics, and the increasing artificial intelligence (AI) integration into clinical settings. At the 

 team spoke on-site with several leaders in the field of skin health about new data and therapeutic advances they anticipate shaping the field in the year ahead.

Featured leaders included Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System; Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital and professor of dermatology and pediatrics at the University of California (UC), San Diego School of Medicine; Neal Bhatia, MD, director of clinical dermatology at Therapeutics Clinical Research in San Diego; Dawn Eichenfield, MD, PhD, associate professor of dermatology and pediatrics at UC San Diego School of Medicine and Rady Children’s Hospital-San Diego; Philip J. Mease, MD, director of rheumatology research at Providence Swedish Medical Center and clinical professor at the University of Washington (UW) School of Medicine; Paul Nghiem, MD, PhD, George F. Odland Endowed Chair in Dermatology at the UW School of Medicine; and Walter J. Liszewski, MD, dermatologist and clinical educator specializing in complex medical dermatology.

Stein Gold noted 2026 may mark “the year of the oral psoriasis therapy,” highlighting anticipation surrounding the potential approval of the oral interleukin (IL)-23 inhibitor icotrokinra and continued development of next-generation TYK2 inhibitors. She pointed to the expansion of oral options as potentially providing patients with efficacy comparable to biologics without compromising safety or tolerability, broadening flexibility in systemic psoriasis.

Lawrence Eichenfield focused on atopic dermatitis, noting several unanswered questions surrounding long-term immunologic modulation. He pointed to differences among biologics targeting IL-4/IL-13 pathways, IL-13 alone, IL-31, and upstream mediators such as OX40 and OX40 ligand. Although clinical endpoints such as Eczema Area and Severity Index (EASI) scores remain central, Eichenfield indicated understanding immunologic “rebooting” after prolonged therapy may shape treatment paradigms in the future, especially among pediatric and adult patients.

Bhatia pointed to excitement around a novel systemic acne therapy, denifanstat, a fatty acid synthase inhibitor targeting de novo lipogenesis to reduce sebum production. Unlike isotretinoin or antibiotics, Bhatia describes this mechanism as addressing a key driver of the pathogenesis of acne without retinoid-associated adverse effects, representing a potential paradigm shift in moderate-to-severe acne management. It is pending additional US-based research.

Dawn Eichenfield highlighted advances in the pediatric dermatology space, particularly highlighting genetic diagnostics and evolving biologic platforms. She suggested oral biologics and medications with extended dosing intervals could improve patient adherence as well as the quality of life of children and adolescents who prefer not to experience injections at an increased frequency.

In Mease’s segment of this interview, he described continued innovation across dermatology and rheumatology, noting small-molecule and biologic therapies aimed at IL-17A/F, IL-23, and TL1A pathways. Mease additionally referenced emerging long-acting biologic options potentially requiring administration only once or twice per year. This development of emerging options reflects efforts to refine molecular configurations for sustained treatment efficacy.

Nghiem spoke in his interview about AI’s growing role in dermatology, particularly in complex malignancies such as Merkel cell carcinoma. While he acknowledged potential overhype, Nghiem emphasized AI’s potential value in expanding patient access to multidisciplinary insights and surfacing considerations clinicians may not initially identify.

In his segment, Liszewski highlighted increasing awareness of chronic hand eczema (CHE) and renewed dermatology engagement in chronic spontaneous urticaria (CSU) management, especially with the emergence of newer agents such as remibrutinib and dupilumab. These drugs, Liszewski highlighted, are reshaping treatment algorithms.

Collectively, these leading experts at Maui Derm Hawaii 2026 signaled a year defined not only by new research and emerging treatment options, but by deeper immunologic understanding, improved personalization of medications, and expanded tools to enhance patient-centered care in the field of dermatology.

For more information on research covered at the 2026 Maui Derm conference, view the full video above or check out the 

Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for Johnson & Johnson. Lawrence Eichenfield previously reported receiving personal fees from Pfizer; grant support from AbbVie, Arcutis Biotherapeutics, Castle Biosciences, Dermavant Sciences, Galderma, Pfizer, Regeneron, and Sanofi; consulting fees from multiple pharmaceutical companies; and serving on the board of directors of Forté Pharma. Bhatia has reported serving as an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals. Dawn Eichenfield had no relevant disclosures of note for this interview. Mease has previously reported receiving research grants from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Sun Pharma and UCB; and serving as a consultant and/or receiving speaker fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galápagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, UCB, Ventyx Biosciences, and XinThera. Liszewski has no disclosures of note.

Stein Gold L, Hawkes J. Best of the Best at Maui Derm. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Eichenfield L, Silverberg J, Chovatiya R. Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Rosen T, Bhatia N. New Drugs and Therapies in 2026. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Eichenfield D, Fallon Friedlander S, Treat J, et al. Pediatric Dermatology 2026. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Stein Gold L, Song E, Gordon K, et al. Psoriasis Update 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Liszewski W. Contact Dermatitis Update 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Sophie Stocker is an Associate Professor in the Sydney Pharmacy School. She is also an Honorary Senior Hospital Scientist in the Department of Clinical Pharmacology and Toxicology at St Vincent's Hospital, Sydney; an Adjunct Senior Lecturer of the St Vincent's Clinical School, University of New South Wales; and an Honorary Scientist at the Garvan Medical Research Institute.

Study investigators suggest further development of a wearable electrochemical aptamer-based patch device could aid precising vancomycin dosing, thereby potentially preventing antibiotic-induced acute kidney injury.

A pilot phase trial testing a wearable patch for continuous drug concentration measurement captured vancomycin levels in 5-minute intervals, demonstrating no safety or pain concerns in 6 participants.

Realtime blood monitoring of antibiotic levels can potentially benefit pediatric patients and those in outpatient settings, pending the ability for clinicians to monitor patients from home.

“It would also be a big win in pediatrics, where blood sampling is complex and clinicians try to minimize it,” said study investigator Sophie Stocker, BsC, PhD, Associate Professor in the Sydney Pharmacy School, an Honorary Senior Hospital Scientist in the Department of Clinical Pharmacology and Toxicology at St Vincent's Hospital, Sydney, an Adjunct Senior Lecturer of the St Vincent's Clinical School, University of New South Wales, and an Honorary Scientist at the Garvan Medical Research Institute, in an interview with 

 “Finally, in the outpatient setting, patients could go home with sensors applied while clinicians continue to receive continuous monitoring data—essentially providing hospital-level care at home. These are the key populations likely to benefit first.”

Vancomycin is the predominant frontline antibiotic clinicians use to treat severe, drug-resistant infections, including those associated with hospital-acquired infections associated with medical devices, caused by coagulase-negative staphylococci. Additionally, it is the primary alternative for patients with a penicillin allergy.

Despite its widespread use and efficacy, vancomycin can cause nephrotoxicity by accumulating in renal proximal tubule cells, leading to oxidative stress, mitochondrial dysfunction, and cellular apoptosis. This effect can be dose-dependent, with an increased risk at elevated concentrations > 20 mg/L or with prolonged therapy. Nephrotoxicity is a major cause of acute kidney injury, and can be linked to 60% of hospital-acquired causes.

Stocker and investigators postured that having a continuous realtime monitoring wearable patch can provide immediate insight into vancomycin levels, thereby giving clinicians the option to adjust the dosage early to prevent acute kidney injury.

Overall, the patches were found to be safe and nearly pain-free, and they captured concentrations of vancomycin in the dermal interstitial fluid with 5-minute resolution over 24 hours. There was sensor degradation observed in participants, so the data primarily focuses on the first 12 hours.

This DNA aptamer sensing technology is very flexible and adaptable. The device developed by Nutromics is modular, so if you can create a DNA aptamer for any target—whether a drug molecule, a kidney function marker, or a toxicity marker—it can be monitored.”

Stocker S, Erdal MK, Larson M, et al. Pilot phase clinical trial of a wearable, electrochemical aptamer-based patch for continuous drug concentration measurement. 

. Published online February 4, 2026. doi:

https://doi.org/10.1038/s41587-026-03010-w

Vazin A, Mahi Birjand M, Darake M. Evaluation of vancomycin therapy in the adult ICUs of a teaching hospital in southern Iran. 

Patel S, Preuss CV, Bernice F. Vancomycin. National Library of Medicine. Published October 29, 2024. 

https://www.ncbi.nlm.nih.gov/books/NBK459263/

Yasrebi-de Kom IAR, Jager KJ, Stel VS, et al. Vancomycin-Induced Acute Kidney Injury in Intensive Care Patients: A Target Trial Emulation Study Using Multicenter Routinely Collected Data. 

Kan WC, Chen YC, Wu VC, Shiao CC. Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application. 

International Journal of Molecular Sciences

Stocker discusses the potential for a wearable patch to continuous drug measurement of vancomycin, especially in pediatric patients and outpatient settings.



Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Wearable Patch May Prevent Acute Kidney Injury

Abraham Kazemi, MD, is the director of Cosmetic and Laser Dermatology for Virginia’s Pinnacle Dermatology sites.

Daily Challenges as a Dermatologist Helping Underserved Patients, With Abrahem Kazemi, MD

Skin of Color Savvy: The Art and Science of Treating Patients of Color

, Abrahem Kazemi, MD, reflects on the evolving challenges and rewards of modern dermatologic practice, highlighting how resilience, clinical expertise, and a commitment to underserved populations intersect in his daily work.

He describes challenge as a constant in dermatology—one that has been shaped in part by his residency training in New York City during the height of the COVID-19 pandemic. Having trained at the New York Medical College Department of Dermatology in Manhattan, he experienced a dramatic shift from routine clinical education to frontline emergency response. Working in special pathogen units and witnessing severe, often fatal cases of respiratory failure, he notes that the experience demanded courage and adaptability. That period, he explains, instilled in him the “thick skin” and decisiveness that now inform his approach to complex dermatologic cases.

In current practice in Northern Virginia, Kazemi sees between 60 and 80 patients per day and is among a limited number of board-certified dermatologists in the state who accept Medicaid. As a result, he frequently manages patients who present with advanced disease due to delayed access to care. He notes that these cases often include advanced skin cancers in rural populations, severe hidradenitis suppurativa, and scarring alopecias in patients of color. Beyond diagnostic and procedural complexity, he identifies treatment adherence and follow-up as ongoing challenges, particularly among patients navigating socioeconomic instability. Education, clear communication, and reinforcement of compliance, he emphasizes, are essential components of care. Despite the obstacles, he frames this work as both a responsibility and a source of professional pride.

The segment also highlights his focused clinical interests in skin of color, alopecias, hidradenitis suppurativa, and complex psoriasis. He discusses the psychosocial burden of hair loss disorders, particularly in women and men of color, and points to expanding therapeutic options as a promising development. Oral minoxidil and dutasteride, among other systemic therapies, are becoming more mainstream, while procedural interventions such as low-level laser therapy, platelet-rich plasma, platelet-rich fibrin, and microneedling are gaining traction within evidence-based frameworks.

He expresses particular interest in central centrifugal cicatricial alopecia (CCCA), noting prior dermatopathologic research correlating fibrosis with disease severity. The condition, he explains, remains underrecognized and often mischaracterized, underscoring the need for specialized expertise in melanin-rich skin. In hidradenitis suppurativa, he highlights the addition of newer biologics to the treatment armamentarium and anticipates the potential impact of emerging oral JAK inhibitors.

Throughout the segment, Kazemi underscores a broader theme: dermatology is rarely “just skin deep.” Clinical acumen must be paired with perseverance, advocacy, and a willingness to care for populations that others may overlook—an ethos that continues to shape his evolving practice.

Editor’s note: This summary was edited with the help of AI tools.

Kazemi A. Skin of Color Savvy: Serving the Underserved in Dermatology, With Abrahem Kazemi, MD. HCPLive. February 16, 2026. Accessed February 17, 2026. 

https://www.hcplive.com/view/skin-of-color-savvy-serving-underserved-dermatology-abrahem-kazemi-md

This clip from the latest episode of the Skin of Color Savvy podcast highlights Kazemi's experiences as a dermatologist working to help underserved communities.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Daily Challenges as a Dermatologist Helping Underserved Patients

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Novo Nordisk Rebrands Rybelsus as Ozempic to Increase Patient Awareness

 approved Ozempic as the proprietary name for Novo Nordisk’s oral semaglutide formulation 1.5 mg, 4 mg, and 9 mg for adult patients with 

. The pill’s active ingredient is the same as the treatment previously known as Rybelsus, meaning the change is effectively a rebrand of an existing drug.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the decision and its expected impact on patient awareness of the drug’s availability and efficacy.

Check out the full episode on oral GLP-1s 

In this segment, the discussion opens with a review of the recent expansion of oral semaglutide options, including higher-dose oral Wegovy and the FDA approval of 14 mg oral semaglutide now branded as Ozempic for type 2 diabetes. Isaacs and Bellini emphasize that this development does not represent a new molecular entity, but rather a reformulation and strategic rebranding of oral semaglutide previously marketed as Rybelsus. Based on bioequivalence data, the updated formulation maintains comparable efficacy, safety, and pharmacokinetic properties to earlier oral semaglutide doses, while offering a more concentrated preparation that simplifies dosing without altering potency.

The cohosts also highlight the practical and administrative simplification achieved through harmonized branding. Historically, clinicians navigated distinct brand identities—Wegovy for weight management and Ozempic for type 2 diabetes—across injectable formulations, while oral semaglutide carried a separate name. This fragmentation often created confusion for patients and added complexity to prior authorizations, particularly given the substantial overlap between type 2 diabetes and obesity in clinical populations. By aligning oral and injectable products under consistent brand identities tied to indication, prescribing discussions become clearer and more intuitive for both clinicians and patients.

The duo notes that name recognition appears to significantly influence patient interest and engagement. While oral semaglutide was previously available, uptake of Rybelsus was perceived as modest. In contrast, rebranding to oral Ozempic—and the introduction of oral Wegovy—has already generated increased patient inquiries, suggesting that familiarity with established GLP-1 receptor agonist brands may enhance acceptance and demand.

Isaacs and Bellini also highlight key pharmacologic and administration considerations. Oral semaglutide must be taken with no more than four ounces of water and separated from other medications to optimize absorption, due to its co-formulated absorption enhancer. Although administered daily, it retains a prolonged half-life of approximately one week, comparable to injectable formulations. The daily schedule reflects bioavailability constraints rather than rapid clearance, and appropriate counseling remains essential—particularly regarding dose holding for pregnancy planning or perioperative management.

Overall, Isaacs and Bellini characterize these updates as a meaningful step toward streamlining GLP-1 receptor agonist therapy. By reducing confusion, simplifying prescribing logistics, and leveraging brand continuity, the transition to oral Ozempic and oral Wegovy may improve access, adherence, and patient-centered care for individuals with type 2 diabetes and obesity.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

1: Novo Nordisk. Novo Nordisk introduces Ozempic Pill; Available in the US Q2 2026. February 4, 2026. Accessed February 17, 2026. 

https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916488

Diabetes Dialogue Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the patient awareness motivation behind Novo Nordisk’s recent announcement.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

In this segment, Dr Cristancho describes a pragmatic follow-up schedule and objective criteria—including early weight-loss benchmarks—to determine whether to continue, adjust, or discontinue non-incretin treatment.

Follow-up structure and objective thresholds for evaluating non-incretin therapy

Dr Cristancho reviews the targeted role of sympathomimetic agents and outlines essential cardiovascular, psychiatric, and drug–drug interaction assessments before initiating non-incretin medications.

Sympathomimetic agents and baseline safety assessment in obesity pharmacotherapy

David Rizik, MD, is an interventional cardiologist at Banner University Health.

Rizik and Morris discuss the Heartflow PCI Navigator and its promising implications for patients – and how they manage that excitement while waiting for trial data.

Balancing Enthusiasm for New Technologies With the Need for Trial Data, With David Rizik, MD, and Michael Morris, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Articles

Experts in nephrology explain the benefits of kidney transplantation, the evolving immunosuppression landscape, and evaluate the risk factors for donors. 


Chronic Kidney Disease

Breaking Down The Kidney Transplant Landscape on National Donor Day

This Q&A summarizes a recent 2026 Maui Derm Hawaii interview with Walter J. Liszewski, MD, regarding contact dermatitis updates.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Summarizing Key Updates in Contact Dermatitis Management 2026, With Walter Liszewski, MD

Real world study shows significant 12- and 18-month attack rate reductions across HAE subtypes and baseline severities following berotralstat initiation.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Sustained HAE Attack Reductions at 18 Months with Berotralstat, With Raffi Tachdjian, MD

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the controversy surrounding Hims and Hers and the risks of compounding GLP-1 formulas.

Type 1 Diabetes

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Dangers of Compounded Oral GLP-1s

MAJESTY, a phase 3 study evaluating obinutuzumab in primary membranous nephropathy, demonstrates positive efficacy and safety.  


MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Explore the safety and long-term effects of PPAR agonists in patients with liver disease, addressing concerns about bone health and medication interactions.

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

This Skin of Color Savvy episode featured Abrahem Kazemi, MD, who speaks on several notable experiences he had as a dermatologist.

Latest News

CORALreef Lipids: Enlicitide Reduces LDL-C in Patients With ASCVD, With Ann Marie Navar, MD, PhD

What’s Next in Dermatology? Dermatologists Weigh In On 2026

Wearable Patch May Prevent Acute Kidney Injury

Daily Challenges as a Dermatologist Helping Underserved Patients

Novo Nordisk Rebrands Rybelsus as Ozempic to Increase Patient Awareness